{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T08:54:49Z","timestamp":1781513689015,"version":"3.54.1"},"reference-count":137,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100014584","name":"Universit\u00e4tsmedizin der Johannes Gutenberg-Universit\u00e4t Mainz","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100014584","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The US Food and Drug Administration approved 45 new drugs and 4 new cellular and gene therapy products in 2025, that is, a total of 49 new medical therapies. Oncology, hematology\/immunotherapy, and cardiovascular\/respiratory drugs remain most frequent. Among oncology drugs, there is a trend for targeting ever smaller subtypes of malignancies and\/or rarer malignancies. Trends over the past 6\u00a0years include steady levels of first-in-indication (about 10%), first-in-class (about 38%), and next-in-class (about 51%) approvals. Along with a large share of approvals in orphan indications (&gt;\u200950%), fast track approval pathways are now regularly representing more than half of all new approvals. While small molecules remain the bedrock of novel medical treatments (about 60%), there is a growing segment of mRNA, gene, and cell-based pharmacological approaches. These data testify to the innovative strength of academia, biotechnology, and established pharmaceutical companies in providing innovative treatments, often related to previously unmet medical needs.<\/jats:p>","DOI":"10.1007\/s00210-026-05193-0","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T02:51:04Z","timestamp":1773197464000},"page":"11157-11179","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A year in pharmacology: new drugs approved by the US food and drug administration in 2025"],"prefix":"10.1007","volume":"399","author":[{"given":"Gizem","family":"Kayki-Mutlu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zinnet Sevval","family":"Aksoyalp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leszek","family":"Wojnowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin C.","family":"Michel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,11]]},"reference":[{"key":"5193_CR1","doi-asserted-by":"publisher","first-page":"5077","DOI":"10.1007\/s00210-025-04020-2","volume":"398","author":"ZS Aksoyalp","year":"2025","unstructured":"Aksoyalp ZS, Kayki-Mutlu G, Wojnowski L, Michel MC (2025) A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2024. Naunyn Schmiedebergs Arch Pharmacol 398:5077\u20135099. https:\/\/doi.org\/10.1007\/s00210-025-04020-2","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"5193_CR2","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1080\/14712598.2025.2561935","volume":"25","author":"C Antozzi","year":"2025","unstructured":"Antozzi C, Fitzgibbon M (2025) An evaluation of nipocalimab for the treatment of generalized myasthenia gravis. Expert Opin Biol Ther 25:1047\u20131058. https:\/\/doi.org\/10.1080\/14712598.2025.2561935","journal-title":"Expert Opin Biol Ther"},{"key":"5193_CR3","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1200\/JCO.23.01134","volume":"42","author":"I Arrillaga-Romany","year":"2024","unstructured":"Arrillaga-Romany I, Gardner SL, Odia Y, Aguilera D, Allen JE, Batchelor T, Butowski N, Chen C, Cloughesy T, Cluster A, de Groot J, Dixit KS, Graber JJ, Haggiagi AM, Harrison RA, Kheradpour A, Kilburn LB, Kurz SC, Lu G, MacDonald TJ, Mehta M, Melemed AS, Nghiemphu PL, Ramage SC, Shonka N, Sumrall A, Tarapore RS, Taylor L, Umemura Y, Wen PY (2024) ONC201 (dordaviprone) in recurrent H3 K27M-mutant diffuse midline glioma. J Clin Oncol 42:1542\u20131552. https:\/\/doi.org\/10.1200\/JCO.23.01134","journal-title":"J Clin Oncol"},{"key":"5193_CR4","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa2404143","volume":"391","author":"CM Ballantyne","year":"2024","unstructured":"Ballantyne CM, Vasas S, Azizad M, Clifton P, Rosenson RS, Chang T, Melquist S, Zhou R, Mushin M, Leeper NJ, Hellawell J, Gaudet D (2024) Plozasiran, an RNA interference agent targeting APOC3, for mixed hyperlipidemia. N Engl J Med 391:899\u2013912. https:\/\/doi.org\/10.1056\/NEJMoa2404143","journal-title":"N Engl J Med"},{"key":"5193_CR5","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1200\/JCO-25-00112","volume":"43","author":"SN Banerjee","year":"2025","unstructured":"Banerjee SN, Van Nieuwenhuysen E, Aghajanian C, D\u2019Hondt V, Monk BJ, Clamp A, Prendergast E, Oaknin A, Ring K, Colombo N, Holloway RW, Rodrigues M, Chon HS, Gourley C, Santin AD, Thaker PH, Gennigens C, Newman G, Salinas E, Youssoufian H, Moore KN, Lustgarten S, O\u2019Malley DM, Van Gorp T, Grisham RN (2025) Efficacy and safety of avutometinib +\/- defactinib in recurrent low-grade serous ovarian cancer: primary analysis of ENGOT-OV60\/GOG-3052\/RAMP 201. J Clin Oncol 43:2782\u20132792. https:\/\/doi.org\/10.1200\/JCO-25-00112","journal-title":"J Clin Oncol"},{"key":"5193_CR6","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.clinthera.2025.07.020","volume":"47","author":"P Beninger","year":"2025","unstructured":"Beninger P (2025) ANDEMBRY (garadacimab-gxii). Clin Ther 47:823\u2013824. https:\/\/doi.org\/10.1016\/j.clinthera.2025.07.020","journal-title":"Clin Ther"},{"key":"5193_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s11845-025-04161-6","author":"L Bibi","year":"2025","unstructured":"Bibi L, Azam H, Yaseen F (2025a) Dordaviprone-the first and only approved treatment option for recurrent H3 K27M-mutant diffuse midline glioma - letter to the editor. Ir J Med Sci. https:\/\/doi.org\/10.1007\/s11845-025-04161-6","journal-title":"Ir J Med Sci"},{"key":"5193_CR8","doi-asserted-by":"publisher","DOI":"10.1007\/s11845-025-04153-6","author":"L Bibi","year":"2025","unstructured":"Bibi L, Azam H, Yaseen F (2025b) Sebetralstat: FDA approves first oral on-demand therapy for hereditary angioedema. Ir J Med Sci. https:\/\/doi.org\/10.1007\/s11845-025-04153-6","journal-title":"Ir J Med Sci"},{"key":"5193_CR9","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/s0140-6736(24)01027-4","volume":"404","author":"R Bissonnette","year":"2024","unstructured":"Bissonnette R, Warren RB, Pinter A, Agner T, Gooderham M, Schuttelaar MLA, Cr\u00e9py MN, Stingeni L, Serra-Baldrich E, Baranowski K, Korn S, Kurvits M, Plohberger U, Strange Vest N, Schliemann S (2024) Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase 3 trials. Lancet 404:461\u2013473. https:\/\/doi.org\/10.1016\/s0140-6736(24)01027-4","journal-title":"Lancet"},{"key":"5193_CR10","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1007\/s40265-025-02215-8","volume":"85","author":"HA Blair","year":"2025","unstructured":"Blair HA (2025a) Avutometinib and defactinib: first approval. Drugs 85:1319\u20131327. https:\/\/doi.org\/10.1007\/s40265-025-02215-8","journal-title":"Drugs"},{"key":"5193_CR11","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1007\/s40265-025-02185-x","volume":"85","author":"HA Blair","year":"2025","unstructured":"Blair HA (2025b) Datopotamab deruxtecan: first approval. Drugs 85:965\u2013975. https:\/\/doi.org\/10.1007\/s40265-025-02185-x","journal-title":"Drugs"},{"key":"5193_CR12","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-025-02252-3","author":"HA Blair","year":"2025","unstructured":"Blair HA (2025c) Dordaviprone: first approval. Drugs. https:\/\/doi.org\/10.1007\/s40265-025-02252-3","journal-title":"Drugs"},{"key":"5193_CR13","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1007\/s40265-025-02239-0","volume":"85","author":"HA Blair","year":"2025","unstructured":"Blair HA (2025d) Sebetralstat: first approval. Drugs 85:1499\u20131505. https:\/\/doi.org\/10.1007\/s40265-025-02239-0","journal-title":"Drugs"},{"key":"5193_CR14","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1007\/s40265-025-02210-z","volume":"85","author":"HA Blair","year":"2025","unstructured":"Blair HA (2025e) Telisotuzumab vedotin: first approval. Drugs 85:1171\u20131176. https:\/\/doi.org\/10.1007\/s40265-025-02210-z","journal-title":"Drugs"},{"key":"5193_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104896","volume":"215","author":"D Brazel","year":"2025","unstructured":"Brazel D, Park CJ, Nagasaka M (2025) The development of zongertinib for HER2-mutant NSCLC. Crit Rev Oncol Hematol 215:104896. https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104896","journal-title":"Crit Rev Oncol Hematol"},{"key":"5193_CR16","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1200\/JCO.24.01008","volume":"42","author":"N Bumma","year":"2024","unstructured":"Bumma N, Richter J, Jagannath S, Lee HC, Hoffman JE, Suvannasankha A, Zonder JA, Shah MR, Lentzsch S, Baz R, Maly JJ, Namburi S, Pianko MJ, Ye JC, Wu KL, Silbermann R, Min CK, Vekemans MC, Munder M, Byun JM, Martinez-Lopez J, Cassady K, DeVeaux M, Chokshi D, Boyapati A, Hazra A, Yancopoulos GD, Sirulnik LA, Rodriguez Lorenc K, Kroog GS, Houvras Y, Dhodapkar MV (2024) Linvoseltamab for treatment of relapsed\/refractory multiple myeloma. J Clin Oncol 42:2702\u20132712. https:\/\/doi.org\/10.1200\/JCO.24.01008","journal-title":"J Clin Oncol"},{"key":"5193_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2022.128928","volume":"74","author":"TM Caldwell","year":"2022","unstructured":"Caldwell TM, Ahn YM, Bulfer SL, Leary CB, Hood MM, Lu WP, Vogeti L, Vogeti S, Kaufman MD, Wise SC, Le Bourdonnec B, Smith BD, Flynn DL (2022) Discovery of vimseltinib (DCC-3014), a highly selective CSF1R switch-control kinase inhibitor, in clinical development for the treatment of tenosynovial giant cell tumor (TGCT). Bioorg Med Chem Lett 74:128928. https:\/\/doi.org\/10.1016\/j.bmcl.2022.128928","journal-title":"Bioorg Med Chem Lett"},{"key":"5193_CR18","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1056\/NEJMoa2415566","volume":"393","author":"F Cardoso","year":"2025","unstructured":"Cardoso F, Parke S, Brennan DJ, Briggs P, Donders G, Panay N, Haseli-Mashhadi N, Block M, Caetano C, Francuski M, Haberland C, Laapas K, Seitz C, Zuurman L (2025) Elinzanetant for vasomotor symptoms from endocrine therapy for breast cancer. N Engl J Med 393:753\u2013763. https:\/\/doi.org\/10.1056\/NEJMoa2415566","journal-title":"N Engl J Med"},{"key":"5193_CR19","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1016\/j.cgh.2024.01.005","volume":"22","author":"JL Carlin","year":"2024","unstructured":"Carlin JL, Polymeropoulos C, Camilleri M, Lembo A, Fisher M, Kupersmith C, Madonick D, Moszczynski P, Smieszek S, Xiao C, Birznieks G, Polymeropoulos MH (2024) The efficacy of tradipitant in patients with diabetic and idiopathic gastroparesis in a phase 3 randomized placebo-controlled clinical trial. Clin Gastroenterol Hepatol 22:2506\u20132516. https:\/\/doi.org\/10.1016\/j.cgh.2024.01.005","journal-title":"Clin Gastroenterol Hepatol"},{"key":"5193_CR20","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1056\/NEJMoa2021713","volume":"383","author":"JD Chalmers","year":"2020","unstructured":"Chalmers JD, Haworth CS, Metersky ML, Loebinger MR, Blasi F, Sibila O, O\u2019Donnell AE, Sullivan EJ, Mange KC, Fernandez C, Zou J, Daley CL (2020) Phase 2 trial of the DPP-1 inhibitor brensocatib in bronchiectasis. N Engl J Med 383:2127\u20132137. https:\/\/doi.org\/10.1056\/NEJMoa2021713","journal-title":"N Engl J Med"},{"key":"5193_CR21","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1056\/NEJMoa2411664","volume":"392","author":"JD Chalmers","year":"2025","unstructured":"Chalmers JD, Burgel PR, Daley CL, De Soyza A, Haworth CS, Mauger D, Loebinger MR, McShane PJ, Ringshausen FC, Blasi F, Shteinberg M, Mange K, Teper A, Fernandez C, Zambrano M, Fan C, Zhang X, Metersky ML (2025) Phase 3 trial of the DPP-1 inhibitor brensocatib in bronchiectasis. N Engl J Med 392:1569\u20131581. https:\/\/doi.org\/10.1056\/NEJMoa2411664","journal-title":"N Engl J Med"},{"key":"5193_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2025.109159","volume":"145","author":"E Chow","year":"2025","unstructured":"Chow E, Miller L, Clearman A, Arnold P, Koenig MK, Russo SN (2025) Doxecitine and doxribtimine treatment in an adult patient with thymidine kinase 2 deficiency. Mol Genet Metab 145:109159. https:\/\/doi.org\/10.1016\/j.ymgme.2025.109159","journal-title":"Mol Genet Metab"},{"key":"5193_CR23","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1038\/s41409-025-02595-1","volume":"60","author":"P Chumnumsiriwath","year":"2025","unstructured":"Chumnumsiriwath P, Vittayawacharin P, Ramos-Perez J, Jeyakumar D, Lee BJ, Doh J, Griffin S, Nguyen M, Hanna RM, Tran MH, Kongtim P, Ciurea SO (2025) Narsoplimab for refractory transplantation-associated thrombotic microangiopathy (TA-TMA) in adult patients receiving allogeneic hematopoietic stem cell transplantation (AHSCT). Bone Marrow Transplant 60:1065\u20131069. https:\/\/doi.org\/10.1038\/s41409-025-02595-1","journal-title":"Bone Marrow Transplant"},{"key":"5193_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115709","volume":"230","author":"GL Cohen","year":"2025","unstructured":"Cohen GL, Coetzee C, Walton CA, Reig Torras O, Chul Cho B, McAdam G, Rojas CI, Medina Rodriguez L, Papai Z, Chan SW, Rapoport BL, Caglevic C, Yanez Weber P, Takahashi T, Kurata T, Song G, Cohen JW, Akala OO, Khanyile R (2025) Pharmacokinetics and bioavailability of pembrolizumab with berahyaluronidase alfa for subcutaneous administration in participants with advanced or metastatic solid tumors: the phase 1 study 3475A\u2013C18. Eur J Cancer 230:115709. https:\/\/doi.org\/10.1016\/j.ejca.2025.115709","journal-title":"Eur J Cancer"},{"key":"5193_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2025.108812","volume":"268","author":"A Corsini","year":"2025","unstructured":"Corsini A, Ginsberg HN, Chapman MJ (2025) Therapeutic PCSK9 targeting: inside versus outside the hepatocyte? Pharmacol Ther 268:108812. https:\/\/doi.org\/10.1016\/j.pharmthera.2025.108812","journal-title":"Pharmacol Ther"},{"key":"5193_CR26","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1007\/s40265-021-01640-9","volume":"81","author":"S Dhillon","year":"2021","unstructured":"Dhillon S (2021) Penpulimab: first approval. Drugs 81:2159\u20132166. https:\/\/doi.org\/10.1007\/s40265-021-01640-9","journal-title":"Drugs"},{"key":"5193_CR27","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1007\/s40265-023-01959-5","volume":"83","author":"S Dhillon","year":"2023","unstructured":"Dhillon S (2023) Sunvozertinib: first approval. Drugs 83:1629\u20131634. https:\/\/doi.org\/10.1007\/s40265-023-01959-5","journal-title":"Drugs"},{"key":"5193_CR28","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000213908","volume":"105","author":"C Dom\u00ednguez-Gonz\u00e1lez","year":"2025","unstructured":"Dom\u00ednguez-Gonz\u00e1lez C, Chiang C, Colson AO, Rebollo Mesa I, Baixauli E, Quan J, VanMeter S, Hirano M (2025) Pyrimidine nucleos(t)ide therapy in patients with thymidine kinase 2 deficiency: a multicenter retrospective chart review study. Neurology 105:e213908. https:\/\/doi.org\/10.1212\/wnl.0000000000213908","journal-title":"Neurology"},{"key":"5193_CR29","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1136\/ard-2023-224691","volume":"83","author":"T D\u00f6rner","year":"2024","unstructured":"D\u00f6rner T, Kaul M, Sz\u00e1nt\u00f3 A, Tseng JC, Papas AS, Pylvaenaeinen I, Hanser M, Abdallah N, Grioni A, Santos Da Costa A, Ferrero E, Gergely P, Hillenbrand R, Avrameas A, Cenni B, Siegel RM (2024) Efficacy and safety of remibrutinib, a selective potent oral BTK inhibitor, in Sj\u00f6gren\u2019s syndrome: results from a randomised, double-blind, placebo-controlled phase 2 trial. Ann Rheum Dis 83:360\u2013371. https:\/\/doi.org\/10.1136\/ard-2023-224691","journal-title":"Ann Rheum Dis"},{"key":"5193_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10112235","author":"L Dresser","year":"2021","unstructured":"Dresser L, Wlodarski R, Rezania K, Soliven B (2021) Myasthenia gravis: epidemiology, pathophysiology and clinical manifestations. J Clin Med. https:\/\/doi.org\/10.3390\/jcm10112235","journal-title":"J Clin Med"},{"key":"5193_CR31","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1056\/NEJMoa041974","volume":"352","author":"B Falini","year":"2005","unstructured":"Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L, La Starza R, Diverio D, Colombo E, Santucci A, Bigerna B, Pacini R, Pucciarini A, Liso A, Vignetti M, Fazi P, Meani N, Pettirossi V, Saglio G, Mandelli F, Lo-Coco F, Pelicci PG, Martelli MF, Party GALW (2005) Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 352:254\u2013266. https:\/\/doi.org\/10.1056\/NEJMoa041974","journal-title":"N Engl J Med"},{"key":"5193_CR32","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.annonc.2025.03.012","volume":"36","author":"E Felip","year":"2025","unstructured":"Felip E, Rojas CI, Schenker M, Kowalski DM, Casarini IA, Csoszi T, Sendur MAN, Martins J, Calles Blanco A, Wang CC, Wang M, Ramirez Fallas RAL, Yoshioka H, Nair S, Song X, Deng X, Lala M, Eiras R, Takahashi T (2025) Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475a\u2013d77 trial. Ann Oncol 36:775\u2013785. https:\/\/doi.org\/10.1016\/j.annonc.2025.03.012","journal-title":"Ann Oncol"},{"key":"5193_CR33","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1007\/s40265-025-02180-2","volume":"85","author":"S Fung","year":"2025","unstructured":"Fung S (2025a) Garadacimab: first approval. Drugs 85:827\u2013832. https:\/\/doi.org\/10.1007\/s40265-025-02180-2","journal-title":"Drugs"},{"key":"5193_CR34","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1007\/s40265-025-02211-y","volume":"85","author":"S Fung","year":"2025","unstructured":"Fung S (2025b) Nipocalimab: first approval. Drugs 85:1185\u20131192. https:\/\/doi.org\/10.1007\/s40265-025-02211-y","journal-title":"Drugs"},{"key":"5193_CR35","doi-asserted-by":"publisher","first-page":"e148","DOI":"10.1210\/clinem\/dgac643","volume":"108","author":"MR Gadelha","year":"2023","unstructured":"Gadelha MR, Gordon MB, Doknic M, Mez\u0151si E, T\u00f3th M, Randeva H, Marmon T, Jochelson T, Luo R, Monahan M, Madan A, Ferrara-Cook C, Struthers RS, Krasner A (2023) ACROBAT edge: safety and efficacy of switching injected srls to oral paltusotine in patients with acromegaly. J Clin Endocrinol Metab 108:e148\u2013e159. https:\/\/doi.org\/10.1210\/clinem\/dgac643","journal-title":"J Clin Endocrinol Metab"},{"key":"5193_CR36","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1001\/jamacardio.2024.0959","volume":"9","author":"D Gaudet","year":"2024","unstructured":"Gaudet D, Pall D, Watts GF, Nicholls SJ, Rosenson RS, Modesto K, San Martin J, Hellawell J, Ballantyne CM (2024) Plozasiran (ARO-APOC3) for severe hypertriglyceridemia: the SHASTA-2 randomized clinical trial. JAMA Cardiol 9:620\u2013630. https:\/\/doi.org\/10.1001\/jamacardio.2024.0959","journal-title":"JAMA Cardiol"},{"key":"5193_CR37","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/s0140-6736(25)00197-7","volume":"405","author":"P Gevaert","year":"2025","unstructured":"Gevaert P, Desrosiers M, Cornet M, Mullol J, De Corso E, Keles Turel N, Maspero J, Fujieda S, Zhang L, Sousa AR, Woods SJ, Davis AM, Schalkwijk S, Edwards D, Ranganathan P, Follows R, Marshall C, Han JK (2025) Efficacy and safety of twice per year depemokimab in chronic rhinosinusitis with nasal polyps (ANCHOR-1 and ANCHOR-2): phase 3, randomised, double-blind, parallel trials. Lancet 405:911\u2013926. https:\/\/doi.org\/10.1016\/s0140-6736(25)00197-7","journal-title":"Lancet"},{"key":"5193_CR38","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jaad.2025.03.008","volume":"93","author":"M Gooderham","year":"2025","unstructured":"Gooderham M, Molin S, Bissonnette R, Worm M, Cr\u00e9py MN, Stingeni L, Warren RB, Schliemann S, Schuttelaar ML, Ferrucci S, Serra-Baldrich E, Silverberg JI, Balita-Crisostomo CL, \u00d8sterdal ML, Plohberger U, Agner T (2025) Long-term safety and efficacy of delgocitinib cream for up to 52 weeks in adults with chronic hand eczema: results of the phase 3 open-label extension DELTA 3 trial following the DELTA 1 and 2 trials. J Am Acad Dermatol 93:95\u2013103. https:\/\/doi.org\/10.1016\/j.jaad.2025.03.008","journal-title":"J Am Acad Dermatol"},{"key":"5193_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-025-03693-5","volume":"20","author":"C Gwaltney","year":"2025","unstructured":"Gwaltney C, Shields A, Love E, Ollis S, Stokes J, Mazar I, Arenson E, Aiudi A, Wirth RJ, Houts C (2025) Initial psychometric evaluation of the Barth syndrome symptom assessment (BTHS-SA) for adolescents and adults in a phase 2 clinical study. Orphanet J Rare Dis 20:199. https:\/\/doi.org\/10.1186\/s13023-025-03693-5","journal-title":"Orphanet J Rare Dis"},{"key":"5193_CR40","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1182\/blood-2014-02-514778","volume":"124","author":"B Gyurkocza","year":"2014","unstructured":"Gyurkocza B, Sandmaier BM (2014) Conditioning regimens for hematopoietic cell transplantation: one size does not fit all. Blood 124:344\u2013353. https:\/\/doi.org\/10.1182\/blood-2014-02-514778","journal-title":"Blood"},{"key":"5193_CR41","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1056\/NEJMoa2409415","volume":"392","author":"HJL Heerspink","year":"2025","unstructured":"Heerspink HJL, Jardine M, Kohan DE, Lafayette RA, Levin A, Liew A, Zhang H, Lodha A, Gray T, Wang Y, Renfurm R, Barratt J (2025) Atrasentan in patients with IgA nephropathy. N Engl J Med 392:544\u2013554. https:\/\/doi.org\/10.1056\/NEJMoa2409415","journal-title":"N Engl J Med"},{"key":"5193_CR42","doi-asserted-by":"publisher","unstructured":"Hockett JJ, Keller ME, Reeves DJ (2025) Toripalimab and penpulimab: targeting PD-1 in recurrent or metastatic nasopharyngeal carcinoma. Ann Pharmacother: 10600280251391430. https:\/\/doi.org\/10.1177\/10600280251391430","DOI":"10.1177\/10600280251391430"},{"key":"5193_CR43","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1007\/s40265-025-02190-0","volume":"85","author":"SM Hoy","year":"2025","unstructured":"Hoy SM (2025a) Mirdametinib: first approval. Drugs 85:977\u2013984. https:\/\/doi.org\/10.1007\/s40265-025-02190-0","journal-title":"Drugs"},{"key":"5193_CR44","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s40291-025-00787-5","volume":"29","author":"SM Hoy","year":"2025","unstructured":"Hoy SM (2025b) Revakinagene taroretcel: first approval. Mol Diagn Ther 29:553\u2013561. https:\/\/doi.org\/10.1007\/s40291-025-00787-5","journal-title":"Mol Diagn Ther"},{"key":"5193_CR45","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-025-02256-z","author":"SM Hoy","year":"2025","unstructured":"Hoy SM (2025c) Taletrectinib: first approval. Drugs. https:\/\/doi.org\/10.1007\/s40265-025-02256-z","journal-title":"Drugs"},{"key":"5193_CR46","doi-asserted-by":"publisher","first-page":"80","DOI":"10.5582\/ddt.2025.01010","volume":"19","author":"S Hu","year":"2025","unstructured":"Hu S, Lyu D, Gao J (2025) Suzetrigine: the first Nav1.8 inhibitor approved for the treatment of moderate to severe acute pain. Drug Discov Ther 19:80\u201382. https:\/\/doi.org\/10.5582\/ddt.2025.01010","journal-title":"Drug Discov Ther"},{"key":"5193_CR47","doi-asserted-by":"publisher","first-page":"2990","DOI":"10.1111\/jce.70086","volume":"36","author":"JE Ip","year":"2025","unstructured":"Ip JE, Coutu B, Ip JH, Noseworthy PA, Parody ML, Rafii F, Sears SF, Singh N, Stambler BS, Tahirkheli NK, Agudelo-Uribe J, Hu D, Shardonofsky S, Sheikh MB, Holz A, Bharucha DB, Camm AJ (2025) Etripamil nasal spray for recurrent paroxysmal supraventricular tachycardia conversion: results from the NODE-303 open-label study. J Cardiovasc Electrophysiol 36:2990\u20133003. https:\/\/doi.org\/10.1111\/jce.70086","journal-title":"J Cardiovasc Electrophysiol"},{"key":"5193_CR48","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1056\/NEJMoa2406673","volume":"391","author":"DJ Jackson","year":"2024","unstructured":"Jackson DJ, Wechsler ME, Jackson DJ, Bernstein D, Korn S, Pfeffer PE, Chen R, Saito J, de Lu\u00edz Martinez G, Dymek L, Jacques L, Bird N, Schalkwijk S, Smith D, Howarth P, Pavord ID (2024) Twice-yearly depemokimab in severe asthma with an eosinophilic phenotype. N Engl J Med 391:2337\u20132349. https:\/\/doi.org\/10.1056\/NEJMoa2406673","journal-title":"N Engl J Med"},{"key":"5193_CR49","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.66.11.3","volume":"66","author":"K Kauper","year":"2025","unstructured":"Kauper K, Nystuen A, Orecchio L, Gonzalez-Lopez E, Lee A, Duncan JL, Stewart JM, Aaberg T Jr. (2025) Long-term durability of ciliary neurotrophic factor-releasing revakinagene taroretcel-lwey in individuals with retinal degenerative disorders. Invest Ophthalmol Vis Sci 66:3. https:\/\/doi.org\/10.1167\/iovs.66.11.3","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"5193_CR50","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s00210-021-02085-3","volume":"394","author":"G Kayki-Mutlu","year":"2021","unstructured":"Kayki-Mutlu G, Michel MC (2021) A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2020. Naunyn Schmiedebergs Arch Pharmacol 394:839\u2013852. https:\/\/doi.org\/10.1007\/s00210-021-02085-3","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"5193_CR51","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s00210-022-02250-2","volume":"395","author":"G Kayki-Mutlu","year":"2022","unstructured":"Kayki-Mutlu G, Aksoyalp ZS, Wojnowski L, Michel MC (2022) A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2021. Naunyn Schmiedebergs Arch Pharmacol 395:867\u2013885. https:\/\/doi.org\/10.1007\/s00210-022-02250-2","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"5193_CR52","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1007\/s00210-023-02465-x","volume":"396","author":"G Kayki-Mutlu","year":"2023","unstructured":"Kayki-Mutlu G, Aksoyalp ZS, Wojnowski L, Michel MC (2023) A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2022. Naunyn Schmiedebergs Arch Pharmacol 396:1619\u20131632. https:\/\/doi.org\/10.1007\/s00210-023-02465-x","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"5193_CR53","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1007\/s00210-024-03063-1","volume":"397","author":"G Kayki-Mutlu","year":"2024","unstructured":"Kayki-Mutlu G, Aksoyalp ZS, Wojnowski L, Michel MC (2024) A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2023. Naunyn Schmiedebergs Arch Pharmacol 397:2949\u20132970. https:\/\/doi.org\/10.1007\/s00210-024-03063-1","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"5193_CR54","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1007\/s40265-025-02208-7","volume":"85","author":"SJ Keam","year":"2025","unstructured":"Keam SJ (2025a) Atrasentan: first approval. Drugs 85:1311\u20131317. https:\/\/doi.org\/10.1007\/s40265-025-02208-7","journal-title":"Drugs"},{"key":"5193_CR55","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-025-02266-x","author":"SJ Keam","year":"2025","unstructured":"Keam SJ (2025b) Imlunestrant: first approval. Drugs. https:\/\/doi.org\/10.1007\/s40265-025-02266-x","journal-title":"Drugs"},{"key":"5193_CR56","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1007\/s40265-025-02178-w","volume":"85","author":"SJ Keam","year":"2025","unstructured":"Keam SJ (2025c) Suzetrigine: first approval. Drugs 85:845\u2013851. https:\/\/doi.org\/10.1007\/s40265-025-02178-w","journal-title":"Drugs"},{"key":"5193_CR57","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1080\/14656566.2025.2487150","volume":"26","author":"I Khan","year":"2025","unstructured":"Khan I, Sahar A, Numra S, Saha N, Nidhi PR (2025) Efficacy and safety of taletrectinib for treatment of ROS1 positive non-small cell lung cancer: a systematic review. Expert Opin Pharmacother 26:765\u2013772. https:\/\/doi.org\/10.1080\/14656566.2025.2487150","journal-title":"Expert Opin Pharmacother"},{"key":"5193_CR58","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1001\/jamacardio.2024.1659","volume":"9","author":"EQ Klug","year":"2024","unstructured":"Klug EQ, Llerena S, Burgess LJ, Fourie N, Scott R, Vest J, Caldwell K, Kallend D, Stein EA (2024) Efficacy and safety of lerodalcibep in patients with or at high risk of cardiovascular disease: a randomized clinical trial. JAMA Cardiol 9:800\u2013807. https:\/\/doi.org\/10.1001\/jamacardio.2024.1659","journal-title":"JAMA Cardiol"},{"key":"5193_CR59","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1080\/1750743X.2025.2545170","volume":"17","author":"DJ Kuter","year":"2025","unstructured":"Kuter DJ, Ghanima W (2025) Evaluating rilzabrutinib in the treatment of immune thrombocytopenia. Immunotherapy 17:767\u2013782. https:\/\/doi.org\/10.1080\/1750743X.2025.2545170","journal-title":"Immunotherapy"},{"key":"5193_CR60","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/ejh.14425","volume":"115","author":"C Labanca","year":"2025","unstructured":"Labanca C, Martino EA, Vigna E, Bruzzese A, Mendicino F, Carida G, Lucia E, Olivito V, Manicardi V, Amodio N, Neri A, Morabito F, Gentile M (2025) Rilzabrutinib for the treatment of immune thrombocytopenia. Eur J Haematol 115:4\u201315. https:\/\/doi.org\/10.1111\/ejh.14425","journal-title":"Eur J Haematol"},{"key":"5193_CR61","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1056\/NEJMoa2511065","volume":"393","author":"X Le","year":"2025","unstructured":"Le X, Kim TM, Loong HH, Prelaj A, Goh BC, Li L, Fang Y, Lu S, Dong X, Wu L, Shinno Y, Daniele G, Yang TY, Kim HR, Ruiter G, Zhao J, Novello S, Miao L, Janne PA, Goto K, Ruttinger D, Descamps T, Brase JC, Bao W, Li R, Brega N, Grassi P, Girard N, Tan DS, Investigators S- (2025) Sevabertinib in advanced HER2-mutant non-small-cell lung cancer. N Engl J Med 393:1819\u20131832. https:\/\/doi.org\/10.1056\/NEJMoa2511065","journal-title":"N Engl J Med"},{"key":"5193_CR62","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1007\/s40265-025-02203-y","volume":"85","author":"A Lee","year":"2025","unstructured":"Lee A (2025a) Fitusiran: first approval. Drugs 85:1073\u20131077. https:\/\/doi.org\/10.1007\/s40265-025-02203-y","journal-title":"Drugs"},{"key":"5193_CR63","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1007\/s40265-025-02207-8","volume":"85","author":"A Lee","year":"2025","unstructured":"Lee A (2025b) Linvoseltamab: first approval. Drugs 85:1329\u20131333. https:\/\/doi.org\/10.1007\/s40265-025-02207-8","journal-title":"Drugs"},{"key":"5193_CR64","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-025-02259-w","author":"A Lee","year":"2025","unstructured":"Lee A (2025c) Rilzabrutinib: first approval. Drugs. https:\/\/doi.org\/10.1007\/s40265-025-02259-w","journal-title":"Drugs"},{"key":"5193_CR65","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1007\/s40265-025-02191-z","volume":"85","author":"A Lee","year":"2025","unstructured":"Lee A (2025d) Vimseltinib: first approval. Drugs 85:985\u2013989. https:\/\/doi.org\/10.1007\/s40265-025-02191-z","journal-title":"Drugs"},{"key":"5193_CR66","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s40291-025-00819-0","volume":"30","author":"A Lee","year":"2026","unstructured":"Lee A (2026) Zopapogene imadenovec: first approval. Mol Diagn Ther 30:169\u2013171. https:\/\/doi.org\/10.1007\/s40291-025-00819-0","journal-title":"Mol Diagn Ther"},{"key":"5193_CR67","doi-asserted-by":"publisher","first-page":"131","DOI":"10.5582\/ddt.2025.01031","volume":"19","author":"D Lu","year":"2025","unstructured":"Lu D, Dou F, Gao J (2025) Fitusiran: the first approved siRNA therapy for hemophilia via reducing plasma antithrombin levels. Drug Discov Ther 19:131\u2013132. https:\/\/doi.org\/10.5582\/ddt.2025.01031","journal-title":"Drug Discov Ther"},{"key":"5193_CR68","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S0140-6736(25)01953-1","volume":"407","author":"A Luckey","year":"2026","unstructured":"Luckey A, Balasegaram M, Barbee LA, Batteiger TA, Broadhurst H, Cohen SE, Delany-Moretlwe S, de Vries HJC, Dionne JA, Gill K, Kenyon C, Kittiyaowamarn R, Lewis D, Mueller JP, Naicker V, O\u2019Brien S, O\u2019Donnell JP, Phanuphak N, Spooner E, Srinivasan S, Taylor SN, Unemo M, Zwane Z, Hook EW 3rd, De Gouveia K, Makowa Mkhize T, Siva S, Gumede L, Kularatne R, Maseko V, Reddy S, Kwedza P, Singh R, Sookan L, Travill D, Chinhiran K, Mongkolrat S, Duangdee C, Satayarak J, Nonenoy S, Thitipatarakorn S, Woodring JV, Chonwattana W, Na-pompet S, Pongchaisit W, Sriviriyakul S, Wansom T, Ermel A, Fortenberry L, Cammarata CL, Lillis R, Cohee A, Dosunmu E, Masinde G, Dixon P, Dombrowski JC, Soge OO, Hoornenborg E, van Dam A, Cuylaerts V, Debaetselier I, Gayet-Ageron A, McLeod SM, Miller A, Cohen S, Johnstone H, Tshehla L, Alirol E, Au C, Bajjali C, Bettiol E, Daram P, Droal A, Elango V, Escot C, Heep M, Hergarden K, Iniguez D, Kornmann G, Louvion J-F, Manuelli M, Renaux J, Richardson M-A (2026) Zoliflodacin versus ceftriaxone plus azithromycin for treatment of uncomplicated urogenital gonorrhoea: an international, randomised, controlled, open-label, phase 3, non-inferiority clinical trial. Lancet 407:147\u2013160. https:\/\/doi.org\/10.1016\/S0140-6736(25)01953-1","journal-title":"Lancet"},{"key":"5193_CR69","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1002\/bcp.70020","volume":"91","author":"R Luo","year":"2025","unstructured":"Luo R, Madan A, Ferrara-Cook CT, Dalvie D, Goulet L, Struthers RS, Krasner AS (2025) Oral paltusotine, a nonpeptide selective somatostatin receptor 2 agonist: mass balance, absolute bioavailability and metabolism in healthy participants. Br J Clin Pharmacol 91:2070\u20132079. https:\/\/doi.org\/10.1002\/bcp.70020","journal-title":"Br J Clin Pharmacol"},{"key":"5193_CR70","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1056\/NEJMoa2503643","volume":"392","author":"TM Maher","year":"2025","unstructured":"Maher TM, Assassi S, Azuma A, Cottin V, Hoffmann-Vold AM, Kreuter M, Oldham JM, Richeldi L, Valenzuela C, Wijsenbeek MS, Clerisme-Beaty E, Coeck C, Gu H, Ritter I, Schlosser A, Stowasser S, Voss F, Weimann G, Zoz DF, Martinez FJ (2025) Nerandomilast in patients with progressive pulmonary fibrosis. N Engl J Med 392:2203\u20132214. https:\/\/doi.org\/10.1056\/NEJMoa2503643","journal-title":"N Engl J Med"},{"key":"5193_CR71","doi-asserted-by":"publisher","first-page":"221","DOI":"10.2147\/BTT.S252580","volume":"15","author":"E Marchesini","year":"2021","unstructured":"Marchesini E, Morfini M, Valentino L (2021) Recent advances in the treatment of hemophilia: a review. Biologics 15:221\u2013235. https:\/\/doi.org\/10.2147\/BTT.S252580","journal-title":"Biologics"},{"key":"5193_CR72","doi-asserted-by":"publisher","first-page":"4076","DOI":"10.1093\/eurheartj\/ehaf364","volume":"46","author":"MS Maron","year":"2025","unstructured":"Maron MS, Gimeno JR, Veselka J, Barriales-Villa R, Claggett BL, Coats CJ, Hegde SM, Januzzi JL, Kulac IJ, Masri A, Nassif ME, Spertus JA, Jacoby DL, Heitner SB, Kupfer S, Malik FI, Wohltman A, Olivotto I (2025) Efficacy of aficamten in patients with obstructive hypertrophic cardiomyopathy and mild symptoms: results from the SEQUOIA-HCM trial. Eur Heart J 46:4076\u20134086. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf364","journal-title":"Eur Heart J"},{"key":"5193_CR73","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1016\/j.jacc.2024.08.015","volume":"84","author":"A Masri","year":"2024","unstructured":"Masri A, Cardoso RN, Abraham TP, Claggett BL, Coats CJ, Hegde SM, Kulac IJ, Lee MMY, Maron MS, Merkely B, Michels M, Olivotto I, Oreziak A, Jacoby DL, Heitner SB, Kupfer S, Malik FI, Meng L, Solomon SD, Wohltman A, Kwong RY, Kramer CM (2024) Effect of aficamten on cardiac structure and function in obstructive hypertrophic cardiomyopathy: SEQUOIA-HCM CMR substudy. J Am Coll Cardiol 84:1806\u20131817. https:\/\/doi.org\/10.1016\/j.jacc.2024.08.015","journal-title":"J Am Coll Cardiol"},{"key":"5193_CR74","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/j.ekir.2022.01.1073","volume":"7","author":"M Mathur","year":"2022","unstructured":"Mathur M, Barratt J, Suzuki Y, Engler F, Pasetti MF, Yarbrough J, Sloan S, Oldach D (2022) Safety, tolerability, pharmacokinetics, and pharmacodynamics of VIS649 (sibeprenlimab), an APRIL-neutralizing IgG(2) monoclonal antibody, in healthy volunteers. Kidney Int Rep 7:993\u20131003. https:\/\/doi.org\/10.1016\/j.ekir.2022.01.1073","journal-title":"Kidney Int Rep"},{"key":"5193_CR75","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12216927","author":"M Mathur","year":"2023","unstructured":"Mathur M, Chan TM, Oh KH, Kooienga L, Zhuo M, Pinto CS, Chacko B (2023) A proliferation-inducing ligand (APRIL) in the pathogenesis of immunoglobulin A nephropathy: a review of the evidence. J Clin Med. https:\/\/doi.org\/10.3390\/jcm12216927","journal-title":"J Clin Med"},{"key":"5193_CR76","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa2305635","volume":"390","author":"M Mathur","year":"2024","unstructured":"Mathur M, Barratt J, Chacko B, Chan TM, Kooienga L, Oh KH, Sahay M, Suzuki Y, Wong MG, Yarbrough J, Xia J, Pereira BJG (2024) A phase 2 trial of sibeprenlimab in patients with IgA nephropathy. N Engl J Med 390:20\u201331. https:\/\/doi.org\/10.1056\/NEJMoa2305635","journal-title":"N Engl J Med"},{"key":"5193_CR77","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/j.bbamcr.2006.10.001","volume":"1773","author":"JA McCubrey","year":"2007","unstructured":"McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, Basecke J, Evangelisti C, Martelli AM, Franklin RA (2007) Roles of the Raf\/MEK\/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 1773:1263\u20131284. https:\/\/doi.org\/10.1016\/j.bbamcr.2006.10.001","journal-title":"Biochim Biophys Acta"},{"key":"5193_CR78","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1056\/NEJMoa2408792","volume":"392","author":"M Metz","year":"2025","unstructured":"Metz M, Gim\u00e9nez-Arnau A, Hide M, Lebwohl M, Mosnaim G, Saini S, Sussman G, Szalewski R, Haemmerle S, Lheritier K, Martzloff E-D, Seko N, Wang P, Zharkov A, Maurer M (2025) Remibrutinib in chronic spontaneous urticaria. N Engl J Med 392:984\u2013994. https:\/\/doi.org\/10.1056\/NEJMoa2408792","journal-title":"N Engl J Med"},{"key":"5193_CR79","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.1182\/blood.2025028584","volume":"145","author":"M Michel","year":"2025","unstructured":"Michel M (2025) Rilzabrutinib, the first-in-class BTK inhibitor for ITP. Blood 145:2810\u20132812. https:\/\/doi.org\/10.1182\/blood.2025028584","journal-title":"Blood"},{"key":"5193_CR80","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/d41573-025-00202-y","volume":"25","author":"A Mullard","year":"2026","unstructured":"Mullard A (2026) First-in-class APRIL inhibitor secures approval for rare kidney disease. Nat Rev Drug Discov 25:9. https:\/\/doi.org\/10.1038\/d41573-025-00202-y","journal-title":"Nat Rev Drug Discov"},{"key":"5193_CR81","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1016\/s0140-6736(24)01556-3","volume":"404","author":"AC Muntau","year":"2024","unstructured":"Muntau AC, Longo N, Ezgu F, Schwartz IVD, Lah M, Bratkovic D, Margvelashvili L, Kiykim E, Zori R, Campistol Plana J, B\u00e9langer-Quintana A, Lund A, Guilder L, Chakrapani A, Mungan HN, Guimas A, Cabrales Guerra IDC, MacDonald A, Ingalls K, Smith N (2024) Effects of oral sepiapterin on blood Phe concentration in a broad range of patients with phenylketonuria (APHENITY): results of an international, phase 3, randomised, double-blind, placebo-controlled trial. Lancet 404:1333\u20131345. https:\/\/doi.org\/10.1016\/s0140-6736(24)01556-3","journal-title":"Lancet"},{"key":"5193_CR82","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.alit.2023.04.003","volume":"73","author":"H Nakagawa","year":"2024","unstructured":"Nakagawa H, Igarashi A, Saeki H, Kabashima K, Tamaki T, Kaino H, Miwa Y (2024) Safety, efficacy, and pharmacokinetics of delgocitinib ointment in infants with atopic dermatitis: a phase 3, open-label, and long-term study. Allergol Int 73:137\u2013142. https:\/\/doi.org\/10.1016\/j.alit.2023.04.003","journal-title":"Allergol Int"},{"key":"5193_CR83","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.bbmt.2010.05.007","volume":"17","author":"ER Nemecek","year":"2011","unstructured":"Nemecek ER, Guthrie KA, Sorror ML, Wood BL, Doney KC, Hilger RA, Scott BL, Kovacsovics TJ, Maziarz RT, Woolfrey AE, Bedalov A, Sanders JE, Pagel JM, Sickle EJ, Witherspoon R, Flowers ME, Appelbaum FR, Deeg HJ (2011) Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies. Biol Blood Marrow Transplant 17:341\u2013350. https:\/\/doi.org\/10.1016\/j.bbmt.2010.05.007","journal-title":"Biol Blood Marrow Transplant"},{"key":"5193_CR84","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1016\/j.medj.2024.10.022","volume":"5","author":"S Nolasco","year":"2024","unstructured":"Nolasco S, Crimi C (2024) Depemokimab, the first ultra-long-acting anti-IL-5 monoclonal antibody for severe eosinophilic asthma. Med 5:1452\u20131455. https:\/\/doi.org\/10.1016\/j.medj.2024.10.022","journal-title":"Med"},{"key":"5193_CR85","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/s2213-2600(24)00368-0","volume":"13","author":"SM Norberg","year":"2025","unstructured":"Norberg SM, Valdez J, Napier S, Kenyon M, Ferraro E, Wheatley M, Parsons-Wandell L, Doran SL, Lankford A, Sabzevari H, Brough DE, Schlom J, Gulley JL, Allen CT (2025) PRGN-2012 gene therapy in adults with recurrent respiratory papillomatosis: a pivotal phase 1\/2 clinical trial. Lancet Respir Med 13:318\u2013326. https:\/\/doi.org\/10.1016\/s2213-2600(24)00368-0","journal-title":"Lancet Respir Med"},{"key":"5193_CR86","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1158\/1535-7163.MCT-21-0206","volume":"20","author":"D Okajima","year":"2021","unstructured":"Okajima D, Yasuda S, Maejima T, Karibe T, Sakurai K, Aida T, Toki T, Yamaguchi J, Kitamura M, Kamei R, Fujitani T, Honda T, Shibutani T, Muramatsu S, Nakada T, Goto R, Takahashi S, Yamaguchi M, Hamada H, Noguchi Y, Murakami M, Abe Y, Agatsuma T (2021) Datopotamab deruxtecan, a novel TROP2-directed antibody-drug conjugate, demonstrates potent antitumor activity by efficient drug delivery to tumor cells. Mol Cancer Ther 20:2329\u20132340. https:\/\/doi.org\/10.1158\/1535-7163.MCT-21-0206","journal-title":"Mol Cancer Ther"},{"key":"5193_CR87","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s40122-024-00697-0","volume":"14","author":"JD Osteen","year":"2025","unstructured":"Osteen JD, Immani S, Tapley TL, Indersmitten T, Hurst NW, Healey T, Aertgeerts K, Negulescu PA, Lechner SM (2025) Pharmacology and mechanism of action of suzetrigine, a potent and selective Na(V)1.8 pain signal inhibitor for the treatment of moderate to severe pain. Pain Ther 14:655\u2013674. https:\/\/doi.org\/10.1007\/s40122-024-00697-0","journal-title":"Pain Ther"},{"key":"5193_CR88","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1080\/13543784.2025.2558656","volume":"34","author":"G Oztosun","year":"2025","unstructured":"Oztosun G, Armstrong A, Hirbe AC (2025) Mirdametinib, an FDA-approved MEK1\/2 inhibitor for adult and pediatric NF1-associated plexiform neurofibromas. Expert Opin Investig Drugs 34:665\u2013673. https:\/\/doi.org\/10.1080\/13543784.2025.2558656","journal-title":"Expert Opin Investig Drugs"},{"key":"5193_CR89","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1001\/jamainternmed.2025.4421","volume":"185","author":"N Panay","year":"2025","unstructured":"Panay N, Joffe H, Maki PM, Nappi RE, Pinkerton JV, Simon JA, Soares CN, Thurston RC, Francuski M, Caetano C, Genga K, Haberland C, Haseli Mashhadi N, Laapas K, Parke S, Seitz C, Schwarz J, Zuurman L (2025) Elinzanetant for the treatment of vasomotor symptoms associated with menopause: a phase 3 randomized clinical trial. JAMA Intern Med 185:1319\u20131327. https:\/\/doi.org\/10.1001\/jamainternmed.2025.4421","journal-title":"JAMA Intern Med"},{"key":"5193_CR90","doi-asserted-by":"publisher","DOI":"10.1186\/s12959-023-00464-9","volume":"21","author":"A Pandrowala","year":"2023","unstructured":"Pandrowala A, Ganatra P, Krishnan VP, Sharma AN, Chavan S, Bodhanwala M, Agarwal B, Hiwarkar P (2023) Narsoplimab for severe transplant-associated thrombotic microangiopathy. Thromb J 21:26. https:\/\/doi.org\/10.1186\/s12959-023-00464-9","journal-title":"Thromb J"},{"key":"5193_CR91","doi-asserted-by":"publisher","unstructured":"Pattar GR, Wirta D, Jerkins G, Paauw J, McLaurin EB, Liu A, Evans DG, Kenyon K, Cline N, Gupta PK, Meng I, Senchyna M (2025) Acoltremon ophthalmic solution 0.003% for signs and symptoms of dry eye disease: results of phase 3 pivotal COMET-2 and COMET-3 studies. Ophthalmology https:\/\/doi.org\/10.1016\/j.ophtha.2025.09.018","DOI":"10.1016\/j.ophtha.2025.09.018"},{"key":"5193_CR92","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1056\/NEJMoa2512133","volume":"394","author":"V Perkovic","year":"2026","unstructured":"Perkovic V, Trimarchi H, Tesar V, Lafayette R, Wong MG, Barratt J, Suzuki Y, Liew A, Zhang H, Carroll K, Jha V, Quevedo A, Han SH, Praga M, Chacko B, Sahay M, Cheung CK, Kooienga L, Walsh M, Xia J, Fajardo C, Shah L, Hafkin J, Rizk DV (2026) Sibeprenlimab in IgA nephropathy - interim analysis of a phase 3 trial. N Engl J Med 394:635\u2013646. https:\/\/doi.org\/10.1056\/NEJMoa2512133","journal-title":"N Engl J Med"},{"key":"5193_CR93","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1200\/JCO-25-00275","volume":"43","author":"M Perol","year":"2025","unstructured":"Perol M, Li W, Pennell NA, Liu G, Ohe Y, De Braud F, Nagasaka M, Felip E, Xiong A, Zhang Y, Fan H, Wang X, Li S, Lai RK, Ran F, Zhang X, Chen W, Bazhenova L, Zhou C (2025) Taletrectinib in ROS1+ non-small cell lung cancer: TRUST. J Clin Oncol 43:1920\u20131929. https:\/\/doi.org\/10.1200\/JCO-25-00275","journal-title":"J Clin Oncol"},{"key":"5193_CR94","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2025.1550670","volume":"16","author":"VM Polymeropoulos","year":"2025","unstructured":"Polymeropoulos VM, Kiely L, Bushman ML, Sutherland EB, Goldberg AR, Pham AX, Miller CR, Mourad R, Davis TR, Pham NV, Morgan DB, Giles AK, Xiao C, Polymeropoulos CM, Birznieks G, Polymeropoulos MH (2025) Motion Syros: tradipitant effective in the treatment of motion sickness; a multicenter, randomized, double-blind, placebo-controlled study. Front Neurol 16:1550670. https:\/\/doi.org\/10.3389\/fneur.2025.1550670","journal-title":"Front Neurol"},{"key":"5193_CR95","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1007\/s40265-014-0314-5","volume":"74","author":"RM Poole","year":"2014","unstructured":"Poole RM (2014) Pembrolizumab: first global approval. Drugs 74:1973\u20131981. https:\/\/doi.org\/10.1007\/s40265-014-0314-5","journal-title":"Drugs"},{"key":"5193_CR96","doi-asserted-by":"publisher","first-page":"4272","DOI":"10.1093\/eurheartj\/ehad596","volume":"44","author":"F Raal","year":"2023","unstructured":"Raal F, Fourie N, Scott R, Blom D, De Vries Basson M, Kayikcioglu M, Caldwell K, Kallend D, Stein E (2023) Long-term efficacy and safety of lerodalcibep in heterozygous familial hypercholesterolaemia: the LIBerate-HeFH trial. Eur Heart J 44:4272\u20134280. https:\/\/doi.org\/10.1093\/eurheartj\/ehad596","journal-title":"Eur Heart J"},{"key":"5193_CR97","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/s2213-8587(24)00313-9","volume":"13","author":"FJ Raal","year":"2025","unstructured":"Raal FJ, Mehta V, Kayikcioglu M, Blom D, Gupta P, Elis A, Turner T, Daniels C, Vest J, Mitchell T, Caldwell K, Bahassi EM, Kallend D, Stein EA (2025) Lerodalcibep and evolocumab for the treatment of homozygous familial hypercholesterolaemia with PCSK9 inhibition (LIBerate-HoFH): a phase 3, randomised, open-label, crossover, non-inferiority trial. Lancet Diabetes Endocrinol 13:178\u2013187. https:\/\/doi.org\/10.1016\/s2213-8587(24)00313-9","journal-title":"Lancet Diabetes Endocrinol"},{"key":"5193_CR98","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.3324\/haematol.2022.282160","volume":"108","author":"J Rausch","year":"2023","unstructured":"Rausch J, Dzama MM, Dolgikh N, Stiller HL, Bohl SR, Lahrmann C, Kunz K, Kessler L, Echchannaoui H, Chen CW, Kindler T, Dohner K, Burrows F, Theobald M, Sasca D, Kuhn MWM (2023) Menin inhibitor ziftomenib (KO-539) synergizes with drugs targeting chromatin regulation or apoptosis and sensitizes acute myeloid leukemia with MLL rearrangement or NPM1 mutation to venetoclax. Haematologica 108:2837\u20132843. https:\/\/doi.org\/10.3324\/haematol.2022.282160","journal-title":"Haematologica"},{"key":"5193_CR99","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1056\/NEJMoa2414108","volume":"392","author":"L Richeldi","year":"2025","unstructured":"Richeldi L, Azuma A, Cottin V, Kreuter M, Maher TM, Martinez FJ, Oldham JM, Valenzuela C, Clerisme-Beaty E, Gordat M, Wachtlin D, Liu Y, Schlecker C, Stowasser S, Zoz DF, Wijsenbeek MS (2025) Nerandomilast in patients with idiopathic pulmonary fibrosis. N Engl J Med 392:2193\u20132202. https:\/\/doi.org\/10.1056\/NEJMoa2414108","journal-title":"N Engl J Med"},{"key":"5193_CR100","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1016\/j.jaip.2025.06.018","volume":"13","author":"MA Riedl","year":"2025","unstructured":"Riedl MA, Bernstein JA, Jacobs JS, Craig T, Banerji A, Perego F, Lumry WR, Wedner HJ, Gierer S, Manning ME, Bordone L, Treadwell S, Lin T, Newman KB, Yarlas A, Cohn DM (2025) Donidalorsen treatment of hereditary angioedema in patients previously on long-term prophylaxis. J Allergy Clin Immunol Pract 13:2381-2389 e2383. https:\/\/doi.org\/10.1016\/j.jaip.2025.06.018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"5193_CR101","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1111\/bjh.15831","volume":"185","author":"E Rivers","year":"2019","unstructured":"Rivers E, Worth A, Thrasher AJ, Burns SO (2019) How I manage patients with Wiskott Aldrich syndrome. Br J Haematol 185:647\u2013655. https:\/\/doi.org\/10.1111\/bjh.15831","journal-title":"Br J Haematol"},{"key":"5193_CR102","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1016\/S0140-6736(25)00628-2","volume":"405","author":"JDC Ross","year":"2025","unstructured":"Ross JDC, Wilson J, Workowski KA, Taylor SN, Lewis DA, Gatsi S, Flight W, Scangarella-Oman NE, Jakielaszek C, Lythgoe D, Powell M, Janmohamed S, Absalon J, Perry C (2025) Oral gepotidacin for the treatment of uncomplicated urogenital gonorrhoea (EAGLE-1): a phase 3 randomised, open-label, non-inferiority, multicentre study. Lancet 405:1608\u20131620. https:\/\/doi.org\/10.1016\/S0140-6736(25)00628-2","journal-title":"Lancet"},{"key":"5193_CR103","doi-asserted-by":"publisher","first-page":"4405","DOI":"10.1158\/1078-0432.CCR-25-1388","volume":"31","author":"M Royce","year":"2025","unstructured":"Royce M, Shah M, Zhang L, Cheng J, Bonner MK, Pegues M, Miller CP, Leu L, Price LSL, Qiu J, Yu J, Truong TM, Dorff SE, Yang Y, Zhang N, Gutierrez-Lugo M, Ricks TK, Pierce WF, Luo Z, Kappel D, Goldberg KB, Shord SS, Tang S, Bhatnagar V, Pazdur R, Kluetz PG, Amiri-Kordestani L (2025) FDA approval summary: datopotamab deruxtecan-dlnk for treatment of patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer. Clin Cancer Res 31:4405\u20134411. https:\/\/doi.org\/10.1158\/1078-0432.CCR-25-1388","journal-title":"Clin Cancer Res"},{"key":"5193_CR104","doi-asserted-by":"publisher","unstructured":"Saara KS, Rani D (2025) Mirdametinib: FDA approved MEK inhibitor for neurofibromatosis type 1. Cancer Chemother Pharmacol 95:101. https:\/\/doi.org\/10.1007\/s00280-025-04827-z","DOI":"10.1007\/s00280-025-04827-z"},{"key":"5193_CR105","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1007\/s10637-025-01588-7","volume":"43","author":"K Sangwan","year":"2025","unstructured":"Sangwan K, Agarwal G (2025) Sunvozertinib: a promising oral EGFR inhibitor approved for NSCLC with EGFR Ex20ins mutations. Invest New Drugs 43:1177\u20131189. https:\/\/doi.org\/10.1007\/s10637-025-01588-7","journal-title":"Invest New Drugs"},{"key":"5193_CR106","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01639-24","volume":"69","author":"NE Scangarella-Oman","year":"2025","unstructured":"Scangarella-Oman NE, Butler DL, Breton J, Brown D, Kasapidis C, Sheets AJ (2025) Efficacy and in vitro activity of gepotidacin against bacterial uropathogens, including subsets with molecularly characterized resistance mechanisms and genotypes\/epidemiological clones, in females with uncomplicated urinary tract infections: results from two global, pivotal, phase 3 trials (EAGLE-2 and EAGLE-3). Antimicrob Agents Chemother 69:e0163924. https:\/\/doi.org\/10.1128\/aac.01639-24","journal-title":"Antimicrob Agents Chemother"},{"key":"5193_CR107","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1002\/ajh.70044","volume":"100","author":"ML Schoettler","year":"2025","unstructured":"Schoettler ML, Pusarla SK, Nangia N, Perales MA, Duarte RF, Grauer A, Rambaldi A (2025) Narsoplimab results in excellent survival in adults and children with hematopoietic cell transplant associated thrombotic microangiopathy (TA-TMA). Am J Hematol 100:2040\u20132051. https:\/\/doi.org\/10.1002\/ajh.70044","journal-title":"Am J Hematol"},{"key":"5193_CR108","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2025.101582","author":"B Sepodes","year":"2026","unstructured":"Sepodes B, Burgos JG, Thirstrup S (2026) European Medicines Agency approvals of new medicines in November and December 2025. The Lancet Regional Health\u2013Europe. https:\/\/doi.org\/10.1016\/j.lanepe.2025.101582","journal-title":"The Lancet Regional Health\u2013Europe"},{"key":"5193_CR109","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2025.2461191","volume":"17","author":"NP Seth","year":"2025","unstructured":"Seth NP, Xu R, DuPrie M, Choudhury A, Sihapong S, Tyler S, Meador J, Avery W, Cochran E, Daly T, Brown J, Rutitzky L, Markowitz L, Kumar S, Beavers T, Bhattacharya S, Chen H, Parge V, Price K, Wang Y, Sukumaran S, Pao Y, Abouzahr K, Elwood F, Duffner J, Roy S, Narayanaswami P, Hubbard JJ, Ling LE (2025) Nipocalimab, an immunoselective FcRn blocker that lowers IgG and has unique molecular properties. Mabs 17:2461191. https:\/\/doi.org\/10.1080\/19420862.2025.2461191","journal-title":"Mabs"},{"key":"5193_CR110","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.188051","author":"S Sherman","year":"2025","unstructured":"Sherman S, Sandusky ZM, Russo D, Zak D, Nardone A, Friel D, Hermida-Prado F, Heraud C, Kuziel G, Verma A, Gaglia G, Kabraji S, Nguyen QD, Santagata S, Fanning SW, Jeselsohn R (2025) Imlunestrant a next-generation oral SERD overcomes ESR1 mutant resistance in estrogen receptor-positive breast cancer. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.188051","journal-title":"JCI Insight"},{"key":"5193_CR111","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-25-0605","author":"F Siegel","year":"2025","unstructured":"Siegel F, Siegel S, Kotynkova K, Karsli Uzunbas G, Korr D, Tomono H, Andersen S, Denney D, Berger M, Schulze VK, Lewis TA, Kaplan B, Golfier S, Mortier J, Hillig RC, Boemer U, Petersen K, Eis K, Williams S, Ruttinger D, Cherniack AD, Loong HH, Goto K, Grassi P, Meyerson M, Greulich H (2025) Sevabertinib, a reversible HER2 inhibitor with activity in lung cancer. Cancer Discov. https:\/\/doi.org\/10.1158\/2159-8290.CD-25-0605","journal-title":"Cancer Discov"},{"key":"5193_CR112","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1097\/gme.0000000000002138","volume":"30","author":"JA Simon","year":"2023","unstructured":"Simon JA, Anderson RA, Ballantyne E, Bolognese J, Caetano C, Joffe H, Kerr M, Panay N, Seitz C, Seymore S, Trower M, Zuurman L, Pawsey S (2023) Efficacy and safety of elinzanetant, a selective neurokinin-1,3 receptor antagonist for vasomotor symptoms: a dose-finding clinical trial (SWITCH-1). Menopause 30:239\u2013246. https:\/\/doi.org\/10.1097\/gme.0000000000002138","journal-title":"Menopause"},{"key":"5193_CR113","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2025.107995","volume":"157","author":"A Sinha","year":"2025","unstructured":"Sinha A, Railkar RA, Castagnini L, Guerra A, Likos A, Lutkiewicz J, Maas BM, Zang X, Roadcap BA, Choi Y, Nahhas GJ, Arriola CS, Bont L, Manzoni P, Ramilo O, Mu\u00f1oz FM, Finelli L, Lee AW (2025) Evaluation of a monoclonal antibody against respiratory syncytial virus, clesrovimab, in infants and children: comprehensive rationale and study design for the late-stage clinical trials. Contemp Clin Trials 157:107995. https:\/\/doi.org\/10.1016\/j.cct.2025.107995","journal-title":"Contemp Clin Trials"},{"key":"5193_CR114","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1007\/s12325-022-02401-0","volume":"40","author":"ES Sinnathamby","year":"2023","unstructured":"Sinnathamby ES, Issa PP, Roberts L, Norwood H, Malone K, Vemulapalli H, Ahmadzadeh S, Cornett EM, Shekoohi S, Kaye AD (2023) Hereditary angioedema: diagnosis, clinical implications, and pathophysiology. Adv Ther 40:814\u2013827. https:\/\/doi.org\/10.1007\/s12325-022-02401-0","journal-title":"Adv Ther"},{"key":"5193_CR115","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1007\/s00125-024-06326-x","volume":"68","author":"JD Smeijer","year":"2025","unstructured":"Smeijer JD, de Vries ST, Kohan DE, Hou FF, Heerspink HJL (2025) Sex differences in response to the endothelin receptor antagonist atrasentan in individuals with type 2 diabetes and chronic kidney disease: a post hoc analysis of the SONAR trial. Diabetologia 68:516\u2013525. https:\/\/doi.org\/10.1007\/s00125-024-06326-x","journal-title":"Diabetologia"},{"key":"5193_CR116","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1186\/s13023-022-02546-9","volume":"17","author":"JY So","year":"2022","unstructured":"So JY, Nazaroff J, Iwummadu CV, Harris N, Gorell ES, Fulchand S, Bailey I, McCarthy D, Siprashvili Z, Marinkovich MP (2022) Long-term safety and efficacy of gene-corrected autologous keratinocyte grafts for recessive dystrophic epidermolysis bullosa. Orphanet J Rare Dis 17:377","journal-title":"Orphanet J Rare Dis"},{"key":"5193_CR117","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115711","volume":"230","author":"G Song","year":"2025","unstructured":"Song G, Erman M, Martinengo GL, Kocsis J, Kunta G, Wang M, Yoshioka H, de Miranda Silva C, Lala M (2025) Model-based dose selection and pharmacokinetic bridging of subcutaneous from intravenous pembrolizumab across indications. Eur J Cancer 230:115711. https:\/\/doi.org\/10.1016\/j.ejca.2025.115711","journal-title":"Eur J Cancer"},{"key":"5193_CR118","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102491","volume":"112","author":"S Stacchiotti","year":"2023","unstructured":"Stacchiotti S, Durr HR, Schaefer IM, Woertler K, Haas R, Trama A, Caraceni A, Bajpai J, Baldi GG, Bernthal N, Blay JY, Boye K, Broto JM, Chen WT, Dei Tos PA, Desai J, Emhofer S, Eriksson M, Gronchi A, Gelderblom H, Hardes J, Hartmann W, Healey J, Italiano A, Jones RL, Kawai A, Leithner A, Loong H, Mascard E, Morosi C, Otten N, Palmerini E, Patel SR, Reichardt P, Rubin B, Rutkowski P, Sangalli C, Schuster K, Seddon BM, Shkodra M, Staals EL, Tap W, van de Rijn M, van Langevelde K, Vanhoenacker FMM, Wagner A, Wiltink L, Stern S, de Van San VM, Bauer S (2023) Best clinical management of tenosynovial giant cell tumour (TGCT): a consensus paper from the community of experts. Cancer Treat Rev 112:102491. https:\/\/doi.org\/10.1016\/j.ctrv.2022.102491","journal-title":"Cancer Treat Rev"},{"key":"5193_CR119","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/s0140-6736(23)00776-6","volume":"402","author":"BS Stambler","year":"2023","unstructured":"Stambler BS, Camm AJ, Alings M, Dorian P, Heidbuchel H, Houtgraaf J, Kowey PR, Merino JL, Mond\u00e9sert B, Piccini JP, Pokorney SD, Sager PT, Verma A, Wharton JM, Bharucha DB, Plat F, Shardonofsky S, Chen M, Ip JE (2023) Self-administered intranasal etripamil using a symptom-prompted, repeat-dose regimen for atrioventricular-nodal-dependent supraventricular tachycardia (RAPID): a multicentre, randomised trial. Lancet 402:118\u2013128. https:\/\/doi.org\/10.1016\/s0140-6736(23)00776-6","journal-title":"Lancet"},{"key":"5193_CR120","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ygyno.2025.06.022","volume":"200","author":"EH Stover","year":"2025","unstructured":"Stover EH, Lee EK, Shapiro GI, Brugge JS, Matulonis UA, Liu JF (2025) The RAS-MEK-ERK pathway in low-grade serous ovarian cancer. Gynecol Oncol 200:22\u201332. https:\/\/doi.org\/10.1016\/j.ygyno.2025.06.022","journal-title":"Gynecol Oncol"},{"key":"5193_CR121","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-025-02257-y","author":"YY Syed","year":"2025","unstructured":"Syed YY (2025) Donidalorsen: first approval. Drugs. https:\/\/doi.org\/10.1007\/s40265-025-02257-y","journal-title":"Drugs"},{"key":"5193_CR122","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/S0140-6736(25)00778-0","volume":"406","author":"JY Tang","year":"2025","unstructured":"Tang JY, Marinkovich MP, Wiss K, McCarthy D, Truesdale A, Chiou AS, Eid E, McIntyre JK, Bailey I, Furukawa LK, Gorell ES, Harris N, Khosla RK, Peter Lorenz H, Lu Y, Nazaroff J, Grachev ID, Moore AJ (2025) Prademagene zamikeracel for recessive dystrophic epidermolysis bullosa wounds (VIITAL): a two-centre, randomised, open-label, intrapatient-controlled phase 3 trial. Lancet 406:163\u2013173. https:\/\/doi.org\/10.1016\/S0140-6736(25)00778-0","journal-title":"Lancet"},{"key":"5193_CR123","doi-asserted-by":"publisher","DOI":"10.1016\/j.gim.2024.101138","volume":"26","author":"WR Thompson","year":"2024","unstructured":"Thompson WR, Manuel R, Abbruscato A, Carr J, Campbell J, Hornby B, Vaz FM, Vernon HJ (2024) Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER. Genet Med 26:101138. https:\/\/doi.org\/10.1016\/j.gim.2024.101138","journal-title":"Genet Med"},{"key":"5193_CR124","doi-asserted-by":"publisher","DOI":"10.3390\/molecules30122645","author":"P Trillo Aliaga","year":"2025","unstructured":"Trillo Aliaga P, Spitaleri G, Attili I, Corvaja C, Battaiotto E, Angelopoulos PA, Del Signore E, Passaro A, de Marinis F (2025) HER2 in non-small cell lung cancer (NSCLC): evolution of the therapeutic landscape and emerging drugs-a long way to the top. Molecules. https:\/\/doi.org\/10.3390\/molecules30122645","journal-title":"Molecules"},{"key":"5193_CR125","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1111\/ajco.14198","volume":"21","author":"MH Umrani","year":"2025","unstructured":"Umrani MH (2025) Penpulimab-kcqx-a breakthrough in nasopharyngeal carcinoma immunotherapy and the urgent need for global access. Asia Pac J Clin Oncol 21:701\u2013702. https:\/\/doi.org\/10.1111\/ajco.14198","journal-title":"Asia Pac J Clin Oncol"},{"key":"5193_CR126","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.70182","volume":"6","author":"R Ur Rehman","year":"2025","unstructured":"Ur Rehman R (2025) Lynozyfic (linvoseltamab): a first-in-class off-the-shelf T-cell redirector for refractory multiple myeloma. EJHaem 6:e70182. https:\/\/doi.org\/10.1002\/jha2.70182","journal-title":"EJHaem"},{"key":"5193_CR127","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1080\/17460913.2025.2460387","volume":"20","author":"F Wagenlehner","year":"2025","unstructured":"Wagenlehner F, Perry CR, Hooton TM, Scangarella-Oman NE, Millns H, Janmohamed S, Kramer M, Kushner P, Powell M, Jarvis E, Dennison J, Sheets A, Butler D, Breton J (2025) Plain language summary: efficacy and safety of gepotidacin, a new oral antibiotic, compared with nitrofurantoin, a commonly used oral antibiotic, for treating uncomplicated urinary tract infection. Future Microbiol 20:265\u2013275. https:\/\/doi.org\/10.1080\/17460913.2025.2460387","journal-title":"Future Microbiol"},{"key":"5193_CR128","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1158\/1078-0432.CCR-16-1568","volume":"23","author":"J Wang","year":"2017","unstructured":"Wang J, Anderson MG, Oleksijew A, Vaidya KS, Boghaert ER, Tucker L, Zhang Q, Han EK, Palma JP, Naumovski L, Reilly EB (2017) ABBV-399, a c-Met antibody-drug conjugate that targets both MET-amplified and c-Met-overexpressing tumors, irrespective of MET pathway dependence. Clin Cancer Res 23:992\u20131000. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-1568","journal-title":"Clin Cancer Res"},{"key":"5193_CR129","doi-asserted-by":"publisher","unstructured":"Wang ES, Montesinos P, Foran J, Erba H, Rodriguez-Arboli E, Fedorov K, Heiblig M, Heidel FH, Altman JK, Baer MR, Ades L, Pettit K, Peterlin P, Papayannidis C, Berthon C, Walter RB, Shah MV, Balasubramanian S, Khawandanah M, Salamero Garcia O, Bergeron J, Madanat YF, Roboz GJ, Ulrickson M, Redner RL, McCloskey J, Pigneux A, de la Fuente Burguera A, Mitra A, Soifer HS, Tabachri M, Zhang Z, Riches M, Corum D, Leoni M, Issa GC, Fathi AT, Komet (2025a) Ziftomenib in relapsed or refractory NPM1-mutated AML. J Clin Oncol 43: 3381\u20133390. https:\/\/doi.org\/10.1200\/JCO-25-01694","DOI":"10.1200\/JCO-25-01694"},{"key":"5193_CR130","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2024.108053","volume":"199","author":"M Wang","year":"2025","unstructured":"Wang M, Xu Y, Huang WT, Su WC, Gao B, Lee CK, Fang J, Zhu X, Yang Z, Janne PA, Yang JC (2025b) Sunvozertinib monotherapy in EGFR tyrosine kinase inhibitor-resistant non-small cell lung cancer with EGFR mutations. Lung Cancer 199:108053. https:\/\/doi.org\/10.1016\/j.lungcan.2024.108053","journal-title":"Lung Cancer"},{"key":"5193_CR131","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1056\/NEJMoa2409368","volume":"392","author":"GF Watts","year":"2025","unstructured":"Watts GF, Rosenson RS, Hegele RA, Goldberg IJ, Gallo A, Mertens A, Baass A, Zhou R, Muhsin M, Hellawell J, Leeper NJ, Gaudet D (2025) Plozasiran for managing persistent chylomicronemia and pancreatitis risk. N Engl J Med 392:127\u2013137. https:\/\/doi.org\/10.1056\/NEJMoa2409368","journal-title":"N Engl J Med"},{"key":"5193_CR132","doi-asserted-by":"publisher","first-page":"e338","DOI":"10.1111\/jdv.17090","volume":"35","author":"SE Welsh","year":"2021","unstructured":"Welsh SE, Xiao C, Kaden AR, Brzezynski JL, Mohrman MA, Wang J, Smieszek SP, Przychodzen B, St\u00e4nder S, Polymeropoulos C, Birznieks G, Polymeropoulos MH (2021) Neurokinin-1 receptor antagonist tradipitant has mixed effects on itch in atopic dermatitis: results from EPIONE, a randomized clinical trial. J Eur Acad Dermatol Venereol 35:e338\u2013e340. https:\/\/doi.org\/10.1111\/jdv.17090","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"5193_CR133","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics15010061","author":"L Yao","year":"2026","unstructured":"Yao L, Tian T, Lu X, Zou D, Tang Z, Feng X, Zheng T, Ning Z, Lin Y, Ye M, Jiang J, Zhou P (2026) In vitro activity of zoliflodacin against Neisseria gonorrhoeae isolates from Shanghai, China (2020-2023). Antibiotics. https:\/\/doi.org\/10.3390\/antibiotics15010061","journal-title":"Antibiotics"},{"key":"5193_CR134","doi-asserted-by":"publisher","first-page":"6910","DOI":"10.1097\/MS9.0000000000003945","volume":"87","author":"FT Zahra","year":"2025","unstructured":"Zahra FT, Naveed F, Fatima M (2025) Taletrectinib in ROS1-positive NSCLC: bridging clinical trials and real-world practice. Ann Med Surg (Lond) 87:6910\u20136912. https:\/\/doi.org\/10.1097\/MS9.0000000000003945","journal-title":"Ann Med Surg (Lond)"},{"key":"5193_CR135","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1056\/NEJMoa2502984","volume":"393","author":"HJ Zar","year":"2025","unstructured":"Zar HJ, Sim\u00f5es EAF, Madhi SA, Ramilo O, Senders SD, Shepard JS, Laoprasopwattana K, Piedrahita J, Novoa JM, Vargas SL, Dionne M, Jackowska T, Liu E, Ishihara Y, Ikeda K, Zhang Y, Railkar RA, Lutkiewicz J, Vora KA, Zang X, Maas BM, Lee AW, Guerra A, Sinha A (2025) Clesrovimab for prevention of RSV disease in healthy infants. N Engl J Med 393:1292\u20131303. https:\/\/doi.org\/10.1056\/NEJMoa2502984","journal-title":"N Engl J Med"},{"key":"5193_CR136","doi-asserted-by":"publisher","first-page":"275","DOI":"10.5582\/ddt.2025.01058","volume":"19","author":"C Zhao","year":"2025","unstructured":"Zhao C, Lu D, Gao J (2025) Telisotuzumab vedotin: the first-in-class c-Met-targeted antibody-drug conjugate granted FDA accelerated approval for treatment of non-squamous non-small cell lung cancer (NSCLC). Drug Discov Ther 19:275\u2013276. https:\/\/doi.org\/10.5582\/ddt.2025.01058","journal-title":"Drug Discov Ther"},{"key":"5193_CR137","doi-asserted-by":"publisher","first-page":"210","DOI":"10.5582\/ddt.2025.01048","volume":"19","author":"Y Zhou","year":"2025","unstructured":"Zhou Y, Zhang W, Sun F (2025) Acoltremon: the first TRPM8 agonist approved for the treatment of dry eye disease. Drug Discov Ther 19:210\u2013211. https:\/\/doi.org\/10.5582\/ddt.2025.01048","journal-title":"Drug Discov Ther"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05193-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05193-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05193-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T08:18:13Z","timestamp":1781511493000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05193-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,11]]},"references-count":137,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["5193"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05193-0","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,11]]},"assertion":[{"value":"2 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"GKM, ZSA, and LW declare no conflict of interest. MCM is or has been within the past 3\u00a0years a consultant and\/or speaker for Apogepha, Astellas, Boehringer Ingelheim, Cipla, Dr. Willmar Schwabe, Insignia, MIP Pharma, Opella, Pierre Fabre, Sanofi, Stiftung M\u00e4nnergesundheit, and Terns Pharmaceuticals.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}}]}}